Trial Profile
A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 [budesonide] in asthmatic infants and children 12 months to 8 years of age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CASTLE-I
- Sponsors MAP Pharmaceuticals
- 23 Feb 2009 Co-primary endpoint 'Daytime symptom score' has not been met.
- 23 Feb 2009 Co-primary endpoint 'Night time symptom score' has not been met.
- 26 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.